Patent · US Active

Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

US11834443B2 · kind B2 · utility

0Cited by

31References

26Claims

0Family size

Assignee

IDORSIA PHARMACEUTICALS LTD · CH

Inventors

Cyrille Lescop
Jasper Dingemanse · Allschwil, CH
Andreas Krause · Frankfurt am Main, DE

Key dates

Filing date	Jul 1, 2022
Grant date	Dec 5, 2023
Priority date	—
Expiry date	Jul 1, 2042

Classification

Technology area (CPC G)Physics
CPC primaryG01N23/20075
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.